1185242-69-6

1185242-69-6 structure

Name: MTIC-d3
Chemical Name: 4-[(1E)-3-(2H3)Methyl-1-triazen-1-yl]-1H-imidazole-5-carboxamide
CAS Number: 1185242-69-6
Molecular Formula: C₅H₅D₃N₆O
Molecular Weight: 171.18
Catalog: Research Areas Cancer
Create Date: 2018-06-17 18:22:07
Modify Date: 2024-02-03 21:48:22
MTIC-d3 is deuterium labeled MTIC. MTIC is the active metabolite of Temozolomide (TMZ). MITC has lower bioavailability in the brain compared with TMZ, because the drug’s permeability through biological barriers and tumor cell membranes affects bioavailability. MITC exhibits low affinity to biological membrane[1].

Name	4-[(1E)-3-(2H3)Methyl-1-triazen-1-yl]-1H-imidazole-5-carboxamide
Synonyms	4-[(1E)-3-(2H3)Methyl-1-triazen-1-yl]-1H-imidazole-5-carboxamide 1H-Imidazole-4-carboxamide, 5-[(1E)-3-(methyl-d3)-1-triazen-1-yl]-

Description	MTIC-d3 is deuterium labeled MTIC. MTIC is the active metabolite of Temozolomide (TMZ). MITC has lower bioavailability in the brain compared with TMZ, because the drug’s permeability through biological barriers and tumor cell membranes affects bioavailability. MITC exhibits low affinity to biological membrane[1].
Related Catalog	Research Areas >> Cancer Research Areas >> Neurological Disease
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Ramalho MJ, et al. Biophysical interaction of temozolomide and its active metabolite with biomembrane models: The relevance of drug-membrane interaction for Glioblastoma Multiforme therapy. Eur J Pharm Biopharm. 2019;136:156-163.